Nicotinic Agonist - History

History

Nicotine has been known for centuries for its intoxicating effect. It was first isolated in 1828 from the tobacco plant by German chemists, Posselt and Reimann.

The discovery of positive effects from nicotine on animal memory was discovered by in vivo researches in the middle of the 1980s. Those researches led to a new era in studies of nicotinic acetylcholine receptor (nAChR) and their stimulation but until then the focus had mainly been on nicotine addiction. The development of nAChR agonists began in the early 1990s after the discovery of nicotine’s positive effects. Some research showed a possible therapy option in preclinical researches. ABT-418 was one of the first in a series of nAChR agonists and it was designed by Abbott Labs. ABT-418 showed significant increase of delayed matching-to-sample (DMTS) performance in matured Macaque apes of different species and sex. ABT-418 has also been examined as a possible treatment to Alzheimer’s disease, Parkinson’s disease and attention-deficit hyperactivity disorder: those experiments showed positive outcomes.

One of the first nAChR active compounds, besides nicotine, that was marketed as a drug was galantamine, a plant alkaloid that works as a weak cholinesterase inhibitor (IC50=5µM) as well as an allosteric sensitizer for nAChRs (EC50=50 nM).

Read more about this topic:  Nicotinic Agonist

Famous quotes containing the word history:

    No event in American history is more misunderstood than the Vietnam War. It was misreported then, and it is misremembered now.
    Richard M. Nixon (b. 1913)

    Those who weep for the happy periods which they encounter in history acknowledge what they want; not the alleviation but the silencing of misery.
    Albert Camus (1913–1960)

    A man acquainted with history may, in some respect, be said to have lived from the beginning of the world, and to have been making continual additions to his stock of knowledge in every century.
    David Hume (1711–1776)